Effect of chemotherapy on the expression of CD8 + CD28-T cells in peripheral blood of non-small-cell lung cancer patients
10.3760/cma.j.issn.1673-422X.2016.05.004
- VernacularTitle:化疗对非小细胞肺癌患者外周血中CD8+CD28-T细胞表达的影响
- Author:
Guanzhong LIANG
;
Yanfeng WANG
;
Fucai HAN
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small-cell lung;
Drug therapy;
CD8-positive T-lymphocytes
- From:
Journal of International Oncology
2016;43(5):335-339
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the expression of CD8 + CD28-T cells in the peripheral blood of non-small-cell lung cancer (NSCLC) patients,and to investigate the effect of chemotherapy on CD8 + CD28-T cells expression and its clinical significance.Methods Flow cytometry was used to evaluate the level of CD8 + CD28-T cells in peripheral blood of 70 untreated NSCLC patients and 60 healthy controls.The association between CD8 + CD28-T cells and the clinical features was analyzed.We also investigated the changes of CD8 + CD28-T cells in 30 NSCLC patients who received chemotherapy by GP (gemcitabine,cisplatin) and NP (navelbine,cisplatin).Results The proportion of CD8 + CD28-T cells in lung cancer group was significantly higher than that in healthy group (59.003％ ± 15.329％ vs.41.036％ ± 15.435％,t =35.904,P =0.001).No correlation was found between CD8 + CD28-T cells expression and the gender (F =1.374,P =0.697),pathological pattern (F =0.779,P =0.509) and clinical stage (F =0.070,P =0.933).But CD8 + CD28-T cells expression was correlated with the age (F =15.038,P =0.001).The level of CD8 + CD28-T cells after NP chemotherapy was lower than that before chemotherapy (55.293％ ± 14.637％ vs.58.793％ ± 12.510％,t =2.017,P =0.044).And the level of CD8 + CD28-T cells after GP chemotherapy was lower than that before chemotherapy (54.127％ ± 13.924％ vs.60.700％ ± 16.401％,t =3.007,P =0.009).Conclusion CD8 + CD28-T cells express highly in NSCLC patients peripheral blood.Chemotherapy down-regulates CD8 + CD28-T cells expression,which provides a new reference for combination with chemotherapy and immunotherapy in NSCLC patients.
